Federal Register / Vol. 87, No. 40 / Tuesday, March 1, 2022 / Notices 11445 

Virginia 26505, Telephone: (304) 285– 

5812; Email: DHartley@cdc.gov. 

The Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. 2022–04260 Filed 2–28–22; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60Day-22–22CX; Docket No. CDC–2022– 

0031] 

Proposed Data Collections Submitted 

for Public Comment and 

Recommendations 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice with comment period. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), in the 

Department of Health and Human 

Services (HHS), as part of its continuing 

effort to reduce public burden, invites 

the general public and other federal 

agencies to take this opportunity to 

comment on proposed and/or 

continuing information collections, as 

required by the Paperwork Reduction 

Act of 1995. This notice invites 

comment on a proposed information 

collection project titled Preferences for 

Longer-Acting Preexposure Prophylaxis 

(LA-PrEP) Methods Among Persons in 

U.S. Populations at Highest Need: A 

Discrete Choice Experiment. The 

proposed project is designed to 

understand preferences for LA-PrEP 

products for HIV prevention among 

potential users and providers. 

DATES: CDC must receive written 

comments on or before May 2, 2022. 

ADDRESSES: You may submit comments, 

identified by Docket No. CDC–2022– 

0031, by either of the following 

methods: 

• Federal eRulemaking Portal: 

Regulations.gov. Follow the instructions 

for submitting comments. 

• Mail: Jeffrey M. Zirger, Information 

Collection Review Office, Centers for 

Disease Control and Prevention, 1600 

Clifton Road NE, MS H21–8, Atlanta, 

Georgia 30329. 

Instructions: All submissions received 

must include the agency name and 

Docket Number. CDC will post, without 

change, all relevant comments to 

regulations.gov. 

Please note: Submit all comments 

through the Federal eRulemaking portal 

(regulations.gov) or by U.S. mail to the 

address listed above. 

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the information collection plan and 

instruments, contact Jeffrey M. Zirger, 

Information Collection Review Office, 

Centers for Disease Control and 

Prevention, 1600 Clifton Road NE, MS 

H21–8, Atlanta, Georgia 30329; phone: 

404–639–7118; Email: omb@cdc.gov. 

SUPPLEMENTARY INFORMATION: Under the 

Paperwork Reduction Act of 1995 (PRA) 

(44 U.S.C. 3501–3520), federal agencies 

must obtain approval from the Office of 

Management and Budget (OMB) for each 

collection of information they conduct 

or sponsor. In addition, the PRA also 

requires federal agencies to provide a 

60-day notice in the Federal Register 

concerning each proposed collection of 

information, including each new 

proposed collection, each proposed 

extension of existing collection of 

information, and each reinstatement of 

previously approved information 

collection before submitting the 

collection to OMB for approval. To 

comply with this requirement, we are 

publishing this notice of a proposed 

data collection as described below. 

OMB is particularly interested in 

comments that will help: 

1. Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

2. Evaluate the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

3. Enhance the quality, utility, and 

clarity of the information to be 

collected; 

4. Minimize the burden of the 

collection of information on those who 

are to respond, including through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submissions 

of responses; and 

5. Assess information collection costs. 

Proposed Project 

Preferences for Longer-Acting 

Preexposure Prophylaxis (LA-PrEP) 

Methods Among Persons in U.S. 

Populations at Highest Need: A Discrete 

Choice Experiment—New—National 

Center for HIV, Viral Hepatitis, STD, 

and TB Prevention (NCHHSTP), Centers 

for Disease Control and Prevention 

(CDC). 

Background and Brief Description 

The 2022–2025 National HIV/AIDS 

Strategy includes a goal of increasing 

pre-exposure prophylaxis (PrEP) 

coverage to 50 percent among persons 

with indications, from a 2017 baseline 

of 13.2 percent. Despite successes in 

development and scale up of daily oral 

PrEP as a biomedical HIV prevention 

product, studies consistently show 

obstacles to its uptake and continuation. 

The Centers for Disease Control and 

Prevention (CDC) and its partners must 

engage in early planning for the 

implementation of longer-acting PrEP 

(LA-PrEP) agents to help achieve the 

U.S. Ending the HIV Epidemic (EHE) 

goal of reducing incident HIV infections 

by 90 percent by 2030. Understanding 

providers’ and priority populations’ 

preferences for different LA-PrEP 

agents, and perceived advantages and 

disadvantages of each product, will be 

critical to estimating future uptake and 

use of the various products that are 

recently or soon likely to become 

available for prescription. 

The goal of this study is to understand 

preferences for LA-PrEP products for 

HIV prevention among potential users 

and providers, including product 

characteristics and other service 

delivery factors that may facilitate or 

hinder future uptake of these products. 

In cooperation with partners, CDC will 

conduct a discrete choice experiment 

(DCE) among providers and potential 

users of LA-PrEP products to elicit their 

preferences for characteristics of LAPrEP and delivery programs to 

maximize uptake of LA-PrEP among 

people in need of HIV prevention 

methods. Results from this experiment 

will be used to identify factors key to 

adoption and implementation of each 

product and increase implementation 

efficiency by identifying strategies to 

support decision making and address 

potential challenges. 

The study design is a cross-sectional, 

online survey comprised of a DCE and 

additional questions to directly elicit 

participant preferences and gather data 

on socioeconomic, behavioral, and 

attitudinal factors. DCE methods are 

based on the principle that products or 


jspears on DSK121TN23PROD with NOTICES1
11446 Federal Register / Vol. 87, No. 40 / Tuesday, March 1, 2022 / Notices 

services are evaluated through their 

multiple features or ‘attributes,’ and that 

an individual’s choice of a product or 

service is a function of the utility of 

each attribute option or ‘level.’ 

Attributes and their corresponding 

levels are chosen to represent the 

features of medications, devices, and 

healthcare services that are relevant to 

a healthcare decision. 

The proposed information collection 

will include two separate DCE surveys: 

One for priority populations and one for 

clinicians. The survey uses an 

experimental design to combine levels 

from each attribute into hypothetical 

product profiles and to pair profiles into 

choice tasks. The experimental design 

will be split into several blocks or 

versions. Each equally sized block will 

have 8–12 questions, and questions will 

not be repeated across blocks. 

Participants will be randomly assigned 

to a block and will see only one block 

when completing the survey instrument. 

The study’s target population 

includes persons ages 18 and older who 

either (1) prescribe PrEP or (2) are in the 

following priority population groups 

selected because they have the highest 

rates of HIV acquisition and are in need 

for HIV prevention services: 

• Gay, bisexual, and other men who 

have sex with men subdivided by race/ 

ethnicity: 

Æ Black/African American, 

Æ Hispanic/Latino, or 

Æ White; 

• Black/African American 

heterosexual persons subdivided by 

biological sex: 

Æ Men or 

Æ Women; 

• Transgender women; and 

• Persons who inject drugs. 

To be eligible for the study, potential 

participants in each of the priority 

population groups must be 18 years of 

age or older, living without HIV, and 

meet the U.S. Public Health Service 

(USPHS) indications for offering PrEP as 

described in the 2021 USPHS Clinical 

Practice Guidelines. 

The study sample will be recruited 

from cities with high numbers of annual 

HIV diagnoses within the 57 priority 

jurisdictions identified as part of the 

EHE initiative. Participants will be 

randomly assigned to a block when they 

are sent their unique DCE survey link 

and will only complete the set of choice 

tasks in that block. Throughout the 

study, we will closely monitor 

recruitment and data collection to 

ensure that screening criteria are being 

met, key demographic groups are 

adequately represented, and survey 

completion rates are acceptable. 

Participation is voluntary. For this 

study, CDC intends to screen 

approximately 9,200 participants and 

enroll 1,840 participants. CDC estimates 

that approximately 15 percent of 

enrolled participants will be removed 

from the analysis due to fraud or 

incomplete data, resulting in a final 

analysis sample size of 1,600 

participants. At 25 minutes per survey 

and 10 minutes per combined screening 

and consent, CDC requests approval for 

an estimated 2,341 annualized burden 

hours. There are no costs to respondents 

other than their time. 

ESTIMATED ANNUALIZED BURDEN HOURS

(Type of) respondents Form name Number of 

respondents 

Number of 

responses 

per 

respondent 

Average 

burden per 

response 

(in hours) 

Total burden 

(in hours) 

Black/African American, Hispanic/ 

Latino, or White men who are gay, 

bisexual or have sex with men, 

ages 18+ in the United States.

Screening & Consent .......................

Survey ..............................................

3,450 

690 

1 

1 

10/60 

25/60 

587 

290 

Black/African American Heterosexual 

Cisgender Men or Women, ages 

18+, in the United States.

Screening & Consent .......................

Survey ..............................................

2,300 

460 

1 

1 

10/60 

25/60 

391 

194 

Transgender Women, ages 18+, in 

the United States.

Screening & Consent .......................

Survey ..............................................

1,150 

230 

1 

1 

10/60 

25/60 

196 

97 

Persons who inject drugs, ages 18+, 

in the United States.

Screening & Consent .......................

Survey ..............................................

1,150 

230 

1 

1 

10/60 

25/60 

196 

97 

Clinical providers who prescribe 

PrEP, in the United States.

Screening & Consent .......................

Survey ..............................................

1,150 

230 

1 

1 

10/60 

25/60 

196 

97 

Total ........................................... ........................................................... ........................ ........................ ........................ 2,341 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Scientific Integrity, Office of Science, 

Centers for Disease Control and Prevention. 

[FR Doc. 2022–04190 Filed 2–28–22; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60Day–22–1286; Docket No. CDC–2022– 

0029] 

Proposed Data Collection Submitted 

for Public Comment and 

Recommendations 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice with comment period. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), as part of 

its continuing effort to reduce public 

burden and maximize the utility of 

government information, invites the 

general public and other federal 

agencies the opportunity to comment on 

a proposed and/or continuing 

information collection, as required by 

the Paperwork Reduction Act of 1995. 

This notice invites comment on a 

proposed information collection project 

titled, Annual Reporting of the Rape 

Prevention and Education (RPE) 

Program. The RPE Program is the 

principal federally funded program 

focused on sexual violence (SV) 

prevention. This data collection allows 


jspears on DSK121TN23PROD with NOTICES1